Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) Equity Average (2022 - 2025)

Stoke Therapeutics has reported Equity Average over the past 4 years, most recently at $330.3 million for Q4 2025.

  • For Q4 2025, Equity Average rose 43.25% year-over-year to $330.3 million; the TTM value through Dec 2025 reached $330.3 million, up 43.25%, while the annual FY2025 figure was $290.7 million, 49.64% up from the prior year.
  • Equity Average for Q4 2025 was $330.3 million at Stoke Therapeutics, up from $321.5 million in the prior quarter.
  • Over five years, Equity Average peaked at $342.5 million in Q2 2025 and troughed at $150.0 million in Q1 2024.
  • A 4-year average of $232.0 million and a median of $221.6 million in 2022 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: decreased 24.77% in 2024 and later soared 93.09% in 2025.
  • Year by year, Equity Average stood at $194.5 million in 2022, then dropped by 14.51% to $166.3 million in 2023, then surged by 38.66% to $230.6 million in 2024, then skyrocketed by 43.25% to $330.3 million in 2025.
  • Business Quant data shows Equity Average for STOK at $330.3 million in Q4 2025, $321.5 million in Q3 2025, and $342.5 million in Q2 2025.